Nachrichten zur Hims & Hers Health Aktie

Why Is Hims & Hers Health (HIMS) Stock Soaring Today

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 9.6% in the afternoon session after JPMorgan initiated…

Why Is Hims & Hers Health (HIMS) Stock Soaring Today

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 9.6% in the afternoon session after JPMorgan initiated…

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight…

How Expanding GLP?1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story

In recent days, Hims & Hers Health expanded its platform so clinicians can prescribe Eli Lilly GLP?1 weight loss treatments,…

Eli Lillys new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the days top trending stock…

HIMS Stock Rises as J.P. Morgan Initiates Coverage with Overweight Rating

On April 24, 2026, Hims & Hers Health Inc (HIMS) saw its shares increase following J.P. Morgans initiation of coverage…

Pivotal-Point Nachverfolgung Hims & Hers Health (HIMS): Vorreiterrolle im Peptid-Markt durch Lockerung der US-Behörden gesichert!

Hims & Hers betreibt eine moderne Telemedizin-Plattform, die Patienten den Zugang zu personalisierten Behandlungen in den Bereichen Gewichtsmanagement, Haarpflege und…

Why Hims & Hers Health Stock Is Surging Now

Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…

Hims rises as J.P. Morgan initiates at Overweight on rich catalyst path

Hims & Hers (HIMS) stock rises as J.P. Morgan started its coverage with an Overweight rating, citing the firms recent…

Hims & Hers (HIMS) Bets Big on Branded GLP-1s — J.P. Morgan Likes What It Sees

Hims & Hers (HIMS) stock jumped 7% after adding Eli Lilly GLP-1 drugs to its platform. J.P. Morgan initiated at…

J.P. Morgan initiates coverage on Hims & Hers with bullish outlook

J.P. Morgan initiates coverage on Hims & Hers with bullish outlook…

Hims & Hers Health (NYSE:HIMS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a research note on Friday. They issued an…

HIMS Maintains Rating by B of A Securities -- Price Target Raised to $32

On October 16, 2023, Hims & Hers Health (HIMS) received a recent update from B of A Securities, where analyst…

Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00

Bank of America lifted their price target on Hims & Hers Health from $30.00 to $32.00 and gave the company…

Hims & Hers price target raised to $32 from $30 at BofA

BofA raised the firm’s price target on Hims Hers (HIMS) to $32 from $30 and keeps a Neutral rating…

After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path

JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according to The…

Hims & Hers initiated with an Overweight at JPMorgan

JPMorgan analyst Cory Carpenter initiated coverage of Hims Hers with an Overweight rating and $35 price target Hims is…

JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook

JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook…

JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook

JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook…

JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook

JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook…

Hims stock price reacts strongly to crucial FDA review

Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a…

Hims & Hers reverses amid doubts on its newest obesity plan

Hims stock reversed lower Thursday despite new efforts in weight loss that connect patients with Eli Lillys self-pay pricing.…

Hims stock falls as GLP-1 shift raises questions on strategy

Hims & Hers Health shares declined on Thursday as investors reacted cautiously to the company’s latest expansion in GLP-1 weight-loss…

Eli Lilly (LLY) Expands Partnership with Hims & Hers

The stock of Hims Hers Health ($HIMS) was up as much as 7% after the company announced that it…

Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership

On April 23, 2026, Hims & Hers announced that it has begun providing access to Eli Lillys GLP-1 weight-loss products…

Hims & Hers likely to be up on LillyDirect announcement, says Leerink

Hims Hers (HIMS) announced access to Eli Lilly (LLY) GLP-1 products through its platform, expanding its weight-loss offering, though…

Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch - Hims & Hers Health (NYSE:HIMS)

Hims & Hers expands GLP-1 access, partners with drugmakers, and addresses estrogen patch shortages amid rising menopause care demand.…

Hims & Hers Health (HIMS) Is Up 19.4% After Expanding GLP-1 Access Via LillyDirect Integration

Earlier this week, Hims & Hers Health said clinicians on its platform can now prescribe Eli Lilly GLP-1 weight loss…

Hims & Hers (HIMS) Stock Jumps 7% After Expanding Eli Lilly GLP-1 Deal

Hims & Hers (HIMS) stock rose 7% after expanding its Eli Lilly deal, adding Zepbound prescriptions to its GLP-1 platform…

+1.37% for Hims & Hers Health stock as Novo Nordisk Wegovy collaboration adds branded therapies

Hims & Hers Health trades at $29.41 today, up 1.37%. Get the latest on HIMS price moves and outlook for…

Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Telehealth provider Him & Hers adds all FDA-approved GLP-1s to platform

Him & Hers announced Thursday that eligible users can now access the full r | Providers can now send prescriptions…

BofA raises Hims and Hers stock price target on Lilly partnership

BofA raises Hims and Hers stock price target on Lilly partnership…

BofA raises Hims and Hers stock price target on Lilly partnership

BofA raises Hims and Hers stock price target on Lilly partnership…

Hims & Hers jumps 7% after expanding partnership with Eli Lilly

Hims & Hers Health (NYSE:HIMS) shares climbed 7% after the company revealed an expansion of its platform that allows healthcare…

Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Hims & Hers adds Lilly GLP-1 treatments to lineup – CEO compares it to Netflix’s early days

?Hims & Hers CEO Andrew Dudum noted that, like Netflix gave users the choice of what they wanted most, Hims…

Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days

Hims & Hers announced that Lilly’s Zepbound, Mounjaro, and Foundayo are now available to providers on the platform, allowing them…

Why Hims & Hers stock surged 7% in a single trading day

Hims & Hers Health stock jumped 7% after expanding its platform to include Eli Lillys GLP-1 weight loss medications. Heres…

LLY Sees Surge as Hims & Hers Expands Prescription Capabilities

On April 23, 2026, Hims & Hers announced an enhancement to its platform, allowing healthcare providers to prescribe Zepbound vials…

Hims & Hers enables Zepbound vials, KwikPen prescribing through LillyDirect

Hims Hers founder and CEO Andrew Dudum said via X, “As of this morning, providers on our platform can…

Hims & Hers stock surges 7% on Eli Lilly partnership expansion

Hims & Hers stock surges 7% on Eli Lilly partnership expansion…

Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in?

Hims Hers Health, Inc. ($HIMS) just caught a regulatory break from the U.S. Food and Drug Administration (FDA), but…

Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS)

On April 20, 2026, Soleil Boughton, the Chief Legal Officer of Hims & Hers Health Inc (HIMS), executed a sale…

Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock

Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock…

Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock

Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock…

Hims & Hers CLO sells 9,463 shares at $30

Hims & Hers Health’s Chief Legal Officer sold 9,463 Class A shares at $30 under a Rule 10b5-1 plan, retaining…

Hims & Hers CFO exercises options, sells shares

Hims & Hers CFO Oluyemi Okupe exercised 12,553 options and sold 19,645 shares at $29.96 under a Rule 10b5-1 plan,…